Select language:  
1800 620 420
Close menu

Genetic screening offers hope for people with aggressive blood cancers

Genomic screening for blood cancer offers Australians with aggressive cancers access to personalised treatments and clinical trials.

  • Diffuse large B-cell lymphoma
  • Hodgkin lymphoma
  • Leukaemia
  • Non-Hodgkin lymphoma
  • Research
  • Treatments and side-effects
Read more
Prof Steven Lane with MoST-LLy patient, Marie Webber

Next-gen research revolutionises blood cancer treatment

Discover how next-gen sequencing is revolutionising blood cancer treatment in Australia, improving AML diagnosis and saving lives.

  • Acute myeloid leukaemia
  • Myeloproliferative neoplasms
  • Research
  • Treatments and side-effects
Read more

Groundbreaking milestone reached

A blood cancer drug 30 years in the making has been approved for use in Australia, giving hope to Australians with myelofibrosis, a rare form of blood cancer.

  • Myeloproliferative neoplasms
  • Research
Read more
Leukaemia Foundation Head of Research Bill Stavreski

Research news – August 2024

Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary new type of treatment that ‘trains’ a patient’s own immune cells to seek out and kill cancer.

  • Research
Read more

Unlocking the Mysteries of Blood Cancer

In the ever-evolving landscape of blood cancer research, the quest to combat blood cancer continues to push boundaries. The New Directions in Leukaemia Research (NDLR) event in Adelaide last month brought together leading minds in the field to discuss breakthroughs, challenges, and the future of leukaemia treatment. From cutting-edge advancements in therapies to the promise of personalised medicine, the conference, sponsored by the Leukaemia Foundation, shed light on the latest discoveries and strategies shaping the fight against leukaemia.

  • Research
Read more

Improving treatment of blood cancers using targeted therapies

Read more
Dr Eric Wenlong Li

Advancing the effective use of targeted therapies for blood cancers while reducing side effects

Read more
Damien D'Silva

Understanding why some Lymphomas are resistant to CAR-T therapy

Read more
Dr Helen Cashman

Rare brain lymphoma needs more research and clinical trials

Access to clinical trials of novel treatments, including immune checkpoint inhibitors and CAR T-cell therapy, could be a game changer for these patients, according to Dr Colm Keane. He is a clinical haematologist at the Princess Alexandra Hospital in Brisbane and a brain lymphoma researcher at the University of Queensland's Frazer Institute.  

  • Clinical trials
  • Research
Read more
Dr Colm Keane

Improving outcomes for cutaneous T-cell lymphoma and cutaneous graft-versus-host disease

Haematologist, Dr Jessica Elliott’s interest is researching T-cell mediated skin disorders, in particular, two clinically similar but biologically divergent conditions – cutaneous T-cell lymphomas (CTCL) (a subtype of skin lymphoma) and cutaneous graft-versus-host disease (GVHD).

  • Research
Read more
Dr Jessica Elliott